Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program
Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program
Active, not recruiting · NCT06253637 · Registry updated 2026-03-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-03-05 | NCT06253637 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 40 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ematologia AOU Careggi | Florence | Italy | 3 |
| Ematologia AOU Policlinico Umberto I | Roma | Italy | 1 |
| Ematologia P.O. Vito Fazzi - Lecce | Lecce | Italy | 1 |